Tag Archives: Pfizer

Are You Aging Well? Ask Pfizer

I’ve just finished taking Pfizer’s #FOGO (Have A Fear of Getting Old?) test on getold.com. I passed with flying colors. The results assured me that I would have a hell of a time aging during these advancing years and that the last lap of my life would be a breeze. Why? I wonder. Was it […]
Posted in healthcare, Op-Ed, Patient Communication, patient education, social media | Also tagged , | Leave a comment

New "Blockbusters" Will Triple Acute Coronary Syndrome Market

The launch of several drugs with “extraordinary blockbuster potential” will more than triple the acute coronary syndrome (ACS) treatment market, from $12.3 billion in 2013 to $43.4 billion by 2023, according to research and consulting firm GlobalData.
Posted in Global, Strategy | Also tagged , , , , , , | Leave a comment

The Rx Firm Tax Exodus: Is Something Wrong with the U.S. System?

As I read the latest reports of yet another big US Rx firm, this time AbbVie, trying to pull off a “tax inversion” takeover of the Irish-based Shire, I couldn’t help but wonder, what the heck is going on here? Right now, it feels like most major US corporations, especially pharmas, are literally running away […]
Posted in Deals, Europe, Global, Guest Blog, Legal, Op-Ed, Strategy | Also tagged , , , , , | Leave a comment

The Long Tail: Behind This Year's Pharm Exec 50

Therapeutic specialization, competitive differentiation, and a finely-tailored value proposition are creating a new drug world of bespoke market niches—and infinite future possibilities for the best of this year’s Pharma 50. The vigorous return of M&A activity to biopharmaceuticals this year brings us back to the question that industry strategists have been posing for years: is […]
Posted in Op-Ed, Strategy | Also tagged , , , | Leave a comment

Merger Mania: When the Music Stops

As expected, the PFE/AZ saga has just begun to play out, and as we listen to the music of mega-mergers once again, I suspect that we will shortly be entering a transition where the tone will become a bit more hostile. Pfizer has been down this road before, when the deal to buy Warner Lambert in 2000 for $90 billion turned somewhat hostile. At […]
Posted in Deals, Guest Blog, Op-Ed | Also tagged , , | 1 Comment
  • Categories

  • Meta